Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer

Abstract

Background and study aims Endoscopic ultrasound (EUS)-guided ablation of pancreatic ductal adenocarcinoma (PDAC) with HybridTherm-Probe (EUS-HTP) is feasible and safe, but the radiological response and ideal tool to measure it have not been investigated yet. The aims of this study were to: 1) assess the radiological response to EUS-HTP evaluating the vital tumor volume reduction rate, Response Evaluation Criteria in Solid Tumors (RECIST1.1) and Choi criteria; 2) determine the prognostic predictive yield of these criteria.

Patients and methods A retrospective analysis was performed of patients with locally advanced PDAC after primary treatment or unfit for chemotherapy prospectively treated by EUS-HTP. Computed tomography scan was performed 1 month after EUS-HTP to evaluate: 1) vital tumor volume reduction rate (VTVRR) by measuring necrosis and tumor volumes through a computer-aided detection system; and 2) RECIST1.1 and Choi criteria.

Results EUS-HTP was feasible in 22 of 31 patients (71 %), with no severe adverse events. Median post-HTP survival was 7 months (1 – 35). Compared to pre-HTP tumor volume, a significant 1-month VTVRR (mean 21.4 %) was observed after EUS-HTP (P = 0.005). We identified through ROC analysis a VTVRR > 11.46 % as the best cut-off to determine post-HTP 6-month survival outcome (AUC = 0.733; sensitivity = 70.0 %, specificity = 83.3 %). This cut-off was significantly associated with longer overall survival (HR = 0.372; P = 0.039). According to RECIST1.1 and Choi criteria, good responders to EUS-HTP were 60 % and 46.7 %, respectively. Good responders according to Choi, but not to RECIST1.1, had longer survival (HR = 0.407; P = 0.04).

Conclusions EUS-HTP induces a significant 1-month VTVRR. This effect is assessed accurately by evaluation of necrosis and tumor volumes. Use of VTVRR and Choi criteria, but not RECIST 1.1 criteria, might identify patients who could benefit clinically from EUS-HTP.

• References

• 1 van Veldhuisen E, van den Oord C, Brada LJ. Dutch Pancreatic Cancer Group and International Collaborative Group on Locally Advanced Pancreatic Cancer. et al. Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. 11. Basel: Cancers; 2019: E976
• 2 Paiella S, De Pastena M, Romeo F. et al. Ablation treatments in unresectable pancreatic cancer. Minerva Chir 2019; 74: 263-269
• 3 Ware MJ, Curtis LT, Wu M. et al. Pancreatic adenocarcinoma response to chemotherapy enhanced with non-invasive radiofrequency evaluated via an integrated experimental/computational approach. Scientific Reports 2017; 7: 3437
• 4 Saccomandi P, Lapergola A, Longo F. et al. Thermal ablation of pancreatic cancer: a systematic literature review of clinical practice and pre-clinical studies. Int J Hyperthermia 2018; 35: 398-418
• 5 Niu L, Chen J, He L. et al. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer. Pancreas 2013; 42: 1143-1149
• 6 Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 2014; 14: 199-208
• 7 Carrara S, Arcidiacono PG, Albarello L. et al. Endoscopic ultrasound-guided application of a new internally gas-cooled radiofrequency ablation probe in the liver and spleen of an animal model: a preliminary study. Endoscopy 2008; 40: 759-763
• 8 Carrara S, Arcidiacono PG, Albarello L. et al. Endoscopic ultrasound-guided application of a new hybrid cryotherm probe in porcine pancreas: a preliminary study. Endoscopy 2008; 40: 321-326
• 9 Petrone MC, Arcidiacono PG, Carrara S. et al. US-guided application of a new hybrid probe in human pancreatic adenocarcinoma: an ex vivo study. Gastrointest Endosc 2010; 71: 1294-1297
• 10 Arcidiacono PG, Carrara S, Reni M. et al. Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer. Gastrointest Endosc 2012; 76: 1142-1151
• 11 Graser A, Becker CR, Reiser MF. et al. Volumetry of metastases from renal cell carcinoma: comparison with the RECIST criteria. Radiologe 2008; 48: 850-856
• 12 Xiao J, Tan Y, Li W. et al. Tumor volume reduction rate is superior to RECIST for predicting the pathological response of rectal cancer treated with neoadjuvant chemoradiation: Results from a prospective study. Oncol Lett 2015; 9: 2680-2686
• 13 Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 1990; 45: 228-247
• 14 Ronot M, Bouattour M, Wassermann J. et al. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist 2014; 19: 394-402
• 15 Choi H, Charnsangavej C, Faria SC. et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753-1759
• 16 Luo Y, Chen J, Huang K. et al. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?. BMC Cancer 2017; 17: 154
• 17 Cai J, Xu D, Liu S. et al. The added value of computer-aided detection of small pulmonary nodules and missed lung cancers. J Thorac Imaging 2018; 33: 390-395
• 18 Ren Y, Ma J, Xiong J. et al. Improved false positive reduction by novel morphological features for computer-aided polyp detection in CT colonography. IEEE J Biomed Health Inform 2019; 23: 324-333
• 19 Tempero MA, Arnoletti JP, Behrman S. et al. Pancreatic adenocarcinoma. J Natl Compr Canc Netw 2010; 8: 972-1017
• 20 Elmunzer BJ, Scheiman JM, Lehman GA. U.S. Cooperative for Outcomes Research in Endoscopy (USCORE). et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012; 366: 1414-1422
• 21 Cotton PB, Eisen GM, Aabakken L. et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010; 71: 446-454
• 22 Nougaret S, Rouanet P, Molinari N. et al. MR Volumetric measurement of low rectal cancer helps predict tumor response and outcome after combined chemotherapy and radiation therapy. Radiology 2012; 263: 409-418
• 23 Ebner L, Roos JE, Christensen JD. et al. Maximum-Intensity-projection and computer-aided-detection algorithms as stand-alone reader devices in lung cancer screening using different dose levels and reconstruction kernels. AJR Am J Roentgenol 2016; 207: 282-288
• 24 Furusato Hunt OM, Lubner MG, Ziemlewicz TJ. et al. the liver segmental volume ratio for noninvasive detection of cirrhosis: comparison with established linear and volumetric measures. J Comput Assist Tomogr 2016; 40: 478-484
• 25 García-Figueiras R, Padhani AR, Baleato-González S. therapy monitoring with functional and molecular MR imaging. Magn Reson Imaging Clin N Am 2016; 24: 261-288
• 26 Granata V, Fusco R, Catalano O. et al. Early assessment of colorectal cancer patients with liver metastases treated with antiangiogenic drugs: The role of intravoxel incoherent motion in diffusion-weighted imaging. PLoS One 2015; 10: e0142876
• 27 Paiella S, De Pastena M, Romeo F. et al. Ablation treatments in unresectable pancreatic cancer. Minerva Chir 2019; 74: 263-269
• 28 Girelli R, Frigerio I, Giardino A. et al. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg 2013; 398: 63-69
• 29 Frigerio I, Girelli R, Giardino A. et al. Short term chemotherapy followed by radiofrequency ablation in stage III pancreatic cancer: results from a single center. J Hepatobiliary Pancreat Sci 2013; 20: 574-577
• 30 Linecker M, Pfammatter T, Kambakamba P. et al. Ablation strategies for locally advanced pancreatic cancer. Dig Surg 2016; 33: 351-359
• 31 Paiella S, De Pastena M, D'Onofrio M. et al. Palliative therapy in pancreatic cancer-interventional treatment with radiofrequency ablation/irreversible electroporation. Transl Gastroenterol Hepatol 2018; 3: 80
• 32 Jacobs A. Radiofrequency ablation for liver cancer. Radiol Technol 2015; 86: 645-664
• 33 Al-Alem I, Pillai K, Akhter J. et al. Heat sink phenomenon of bipolar and monopolar radiofrequency ablation observed using polypropylene tubes for vessel simulation. Surg Innov 2014; 21: 269-276
• 34 Signoretti M, Valente R, Repici A. et al. Endoscopy-guided ablation of pancreatic lesions: Technical possibilities and clinical outlook. World J Gastrointest Endosc 2017; 9: 41-54
• 35 Han J, Chang KJ. Endoscopic ultrasound-guided direct intervention for solid pancreatic tumors. Clin Endosc 2017; 50: 126-137